<DOC>
	<DOCNO>NCT00608374</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , chlorambucil fludarabine , work different way stop growth cancer cell , either kill cell stop dividing . It yet know whether chlorambucil effective fludarabine treat Waldenström macroglobulinemia , splenic lymphoma , lymphoplasmacytic lymphoma . PURPOSE : This randomized phase III trial study chlorambucil see well work compare fludarabine first-line therapy treat patient previously untreated Waldenström macroglobulinemia , splenic lymphoma , lymphoplasmacytic lymphoma .</brief_summary>
	<brief_title>Chlorambucil Fludarabine First-Line Therapy Treating Patients With Previously Untreated Waldenström Macroglobulinemia , Splenic Lymphoma , Lymphoplasmacytic Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy first-line therapy comprise chlorambucil v fludarabine phosphate patient previously untreated Waldenström macroglobulinemia , splenic lymphoma villous lymphocyte , non-IgM lymphoplasmacytic lymphoma . OUTLINE : This multicenter study . Patients stratify accord disease ( Waldenström macroglobulinemia v splenic lymphoma villous lymphocyte v non-IgM lymphoplasmacytic lymphoma ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral chlorambucil day 1-10 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . - Arm II : Patients receive fludarabine phosphate orally IV day 1-5 . Treatment repeat every 28 day 3-6 course absence disease progression unacceptable toxicity . Patients undergo quality life assessment baseline .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Waldenström macroglobulinemia , splenic lymphoma villous lymphocyte ( SLVL ) , nonIgM lymphoplasmacytic lymphoma base morphological immunophenotypic criterion Bone marrow assess twocolor flow cytometry expression follow antigen : Surface Ig CD19 CD20 CD5 CD10 CD23 Previously untreated disease require therapeutic intervention ( judged primary physician ) , indicate ≥ 1 following : Hemoglobin &lt; 10 g/dL ANC &lt; 1.5 x 10^9/L Platelet count &lt; 150 x 10^9/L Clinical evidence hyperviscosity term neurological ocular disturbance Patients disease detect clonal cell alone eligible PATIENT CHARACTERISTICS : Performance status 02 Life expectancy &gt; 6 month Serum creatinine &lt; 200 mmol/L AST ALT &lt; 2 time upper limit normal Negative direct Coomb 's test Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 6 month completion study therapy No severe lifethreatening cardiac , pulmonary , neurological , psychiatric , metabolic disease No concurrent malignancy No AIDS AIDSrelated complex No evidence active hepatitis C infection PRIOR CONCURRENT THERAPY : Prior plasmapheresis control clinically significant hyperviscosity allow Prior splenectomy SLVL allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
</DOC>